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Background: Autism and Autism Spectrum Disorder (ASD) are complex neurodevelopmental disorders.
Susceptibility is believed to be the interaction of genetic heritability and environmental factors. The synchronous
rises in autism/ASD prevalence and paracetamol (acetaminophen) use, as well as biologic plausibility have led to
the hypothesis that paracetamol exposure may increase autism/ASD risk.
Methods: To explore the relationship of antenatal paracetamol exposure to ASD, population weighted average
autism prevalence rates and paracetamol usage rates were compared. To explore the relationship of early neonatal
paracetamol exposure to autism/ASD, population weighted average male autism prevalence rates for all available
countries and U.S. states were compared to male circumcision rates – a procedure for which paracetamol has been
widely prescribed since the mid-1990s. Prevalence studies were extracted from the U.S. Centers for Disease Control
and Prevention Summary of Autism/ASD Prevalence Studies database. Maternal paracetamol usage and
circumcision rates were identified by searches on Pub Med.
Results: Using all available country-level data (n = 8) for the period 1984 to 2005, prenatal use of paracetamol was
correlated with autism/ASD prevalence (r = 0.80). For studies including boys born after 1995, there was a strong
correlation between country-level (n = 9) autism/ASD prevalence in males and a country’s circumcision rate
(r = 0.98). A very similar pattern was seen among U.S. states and when comparing the 3 main racial/ethnic groups
in the U.S. The country-level correlation between autism/ASD prevalence in males and paracetamol was
considerably weaker before 1995 when the drug became widely used during circumcision.
Conclusions: This ecological analysis identified country-level correlations between indicators of prenatal and
perinatal paracetamol exposure and autism/ASD. State level correlation was also identified for the indicator of
perinatal paracetamol exposure and autism/ASD. Like all ecological analyses, these data cannot provide strong
evidence of causality. However, biologic plausibility is provided by a growing body of experimental and clinical
evidence linking paracetamol metabolism to pathways shown to be important in autism and related
developmental abnormalities. Taken together, these ecological findings and mechanistic evidence suggest the need
for formal study of the role of paracetamol in autism.
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Autism Spectrum Disorder (ASD) is a severe develop-
mental disorder defined by social deficits, communica-
tion deficits, repetitive behaviors and fixated interests
that appear in early childhood [1,2]. Despite a large
and rapidly expanding body of literature, the etiology
of ASD remains poorly understood. There is substan-
tial evidence implicating oxidative stress, inflammation
and immune dysregulation, although no single coher-
ent explanation has emerged [3]. Recent twin studies
provide evidence that susceptibility to ASD may have
significant environmental components, in addition to
genetic heritability [4,5].
Several lines of evidence suggest that medication use in
pregnancy and early childhood may play a role in ASD
etiology. Specifically, Torres and, Becker and Schultz, have
hypothesized that paracetamol (acetaminophen, N-acetyl-
p-aminophenol, or APAP) has increased ASD risk [6,7]. It
has been shown that autistic children have a decreased
capacity to sulfate paracetamol, which is the primary
metabolic route for children [8]. When paracetamol is
metabolized through the alternative routes it has been
shown in humans to induce oxidative stress and im-
mune dysregulation [9]. A recent investigation found
transcriptomic changes in full-genome human miRNA
expression indicating, for the first time, immune modu-
lating effects and oxidative stress responses to paraceta-
mol even at low doses [10]. Studies in animals have
shown paracetamol to induce apoptosis and neurotoxicity
[11,12]. Several studies hypothesize increased apoptosis in
the autistic brain [13-16].
Paracetamol is one of the most common antipyretic
analgesic medicines worldwide. In 1980, after sufficient
evidence emerged of an association between salicylates
and Reyes syndrome, paracetamol essentially replaced
aspirin as the primary treatment of fever in children and
pregnant women [17,18]. Since that date, paracetamol
consumption throughout the world has increased dra-
matically [19]. Paracetamol sales in the United States
(US) have had a continual upward trend. In 1982, US
paracetamol sales were approximately $400 million; by
2008 they had risen to $2.6 billion [20,21]. Although
prevalence data for autism and ASD are of uncertain accur-
acy, many authors report strong increases in prevalence
over this same time period. Theoharides and col-
leagues for example reported prevalence prior to 1980
as approximately 4/10,000 and Baio et al. estimated
that US autism/ASD prevalence to have risen to about
110/10,000 today [22,23].
Observing the correlation between two parallel time
trends is of limited inferential utility; however the para-
cetamol – ASD link is strengthened by an observation
first made by Becker and Schultz [7]. In 1982 and again
in 1986, product tampering led to a few bottles of aleading brand of paracetamol tablets being contaminated
with cyanide. In each case, a rapid and brief decline in
paracetamol sales occurred, with the long term upward
trend recovering within a year. In three populations for
which good data are available, Becker and Schultz noted
that brief dips in the rising autism prevalence curves
mirrored these sales anomalies. The prevalence curves
continued their upward trend after 1988.
Study aims
Several lines of evidence suggest that the etiologically
relevant period for the development of ASD may be in
utero or possibly in early infancy [24,25]. We sought
additional evidence to test the hypothesis that use of
paracetamol in pregnancy or in early childhood might be
a risk factor for ASD. Studies have reported population
variation in prescribing patterns and usage rates which
has allowed us an opportunity to investigate the correl-
ation between prenatal exposure to paracetamol and aut-
ism spectrum disorder prevalence.
Additionally, we noted that analgesic prescribing habits
for neonates and infants changed in the mid 1990’s with a
shift in perspective on neonatal pain which has afforded
us an additional opportunity to look at population vari-
ation in analgesic use [26]. Research beginning in the
1980’s documented the negative consequences associated
with inadequate treatment of pain in children [27-29].
Pain guidelines specifically for children were established in
1992 by the Agency for Health Care Policy and Research,
in 1998 by the World Health Organization and in 2001 by
the American Academy of Pediatrics [30-33].
A common neonatal medical procedure is circumcision,
which typically occurs during the postpartum hospital
stay, within the first two days of life for a vaginal delivery
and first four days for a cesarean section [34]. Prior to the
1990’s circumcision was generally performed without anal-
gesics. A 1994 study by Howard et al. found that when
paracetamol is given regularly every 6 hours for at least
the first 24-hour postoperative period, infants demon-
strated decreased responses to pain [35]. This study lead
to the development of circumcision pain management
guidelines by the American Academy of Pediatrics [36]
and others [37-39]. These guidelines include the sugges-
tion of a first dose of paracetamol two hours prior to the
procedure, and doses every 4–6 hours for 24 hours follow-
ing the procedure. Thus newborn males often receive 5–7
doses of paracetamol during the developmentally vul-
nerable initial days of life. Variations in circumcision
frequency in different populations allowed us an add-
itional approach to investigate the correlation between
paracetamol use and ASD prevalence. This hypothesis
seemed particularly relevant in light of the approxi-
mately 4.6 times higher prevalence of autism in males
compared to females [23].
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Two separate analyses were conducted. The first exam-
ined the association between prenatal paracetamol ex-
posure and ASD prevalence using maternal usage data
as a proxy for prenatal exposure. The second analysis
investigated the association between circumcision rates
as a proxy for early life paracetamol exposure in males
and ASD prevalence.
Data for investigating prenatal paracetamol exposure and
autism prevalence
To investigate the relationship of ASD to prenatal expos-
ure to paracetamol, population maternal paracetamol
usage rates were compared to population autism preva-
lence rates for as many countries as available data permit-
ted. The population autism prevalence rates utilized were
from studies reported in the U.S. Centers for Disease Con-
trol and Prevention Autism Prevalence Summary Table
[40]. The maternal paracetamol usage rates by country
were drawn from studies identified by a systematic search
of the peer reviewed medical literature using the National
Library of Medicine’s Pub Med database.
Autism prevalence rates
The Autism Prevalence Summary Table from the Center
for Disease Control website [40] summarized the results
of 59 prevalence studies conducted worldwide. This
table recorded the author, year published, country, time
period studied, age range studied, number of children in
the population, the identification criteria, the methodology
used and the prevalence. The oldest and youngest birth
years in each study were calculated based on the time
period and age range studied. Each study was extracted to
verify the table results and to identify the ratio of males to
females to calculate the male prevalence of autism/ASD.
Generally, the CDC Prevalence Summary Table reported
the more narrowly defined autism rate rather than the
more inclusive diagnosis of autism spectrum disorder
(ASD). The CDC Prevalence Summary reported the ASD
rate for the Kim 2011 study in South Korea; however for
consistency with all other results, the more narrowly de-
fined autism rate was extracted and utilized in this analysis
[41]. Two older studies referred to in the CDC table could
not be located and were excluded (Lotter et al. 1966)
(Brask et al. 1970). Two additional study were excluded,
the first because of incomplete case ascertainment [42]
and the second because of lack of total population data
[43]. A total of 55 studies from the CDC summary were
utilized in this analysis (Additional file 1).
Prenatal paracetamol usage rates
Maternal paracetamol usage rates were extracted from
studies examining the use of paracetamol in pregnancy
and relationships to other outcomes. A search of theEnglish language literature on Pub Med was conducted
for the past 20 years with a search date of April 18, 2012
using the terms prenatal, maternal, pregnancy, acet-
aminophen, paracetamol, medication, drugs, analgesic,
pain relief, over the counter, and the different country
names. Various combinations of the terms were used to
maximize the results. If a study appeared to be relevant
it was extracted and reviewed to identify a maternal
paracetamol usage rate. If data were found only for overall
analgesics, nervous system drugs, all over the counter
medications or all western pharmaceuticals an assumption
was made that paracetamol use represented 80%, 80%,
70% and 60%, respectively. These proportions were
established a priori, conservatively approximated based on
the findings of the US National Birth Defects Prevention
Study and used for all studies regardless of country [18].
This literature search yielded 33 studies with medication
usage rates for 14 out of 17 countries with autism preva-
lence rates. Two studies were excluded because they were
subsets of two included studies to yield a total of 31 stud-
ies [44,45]. If multiple studies were identified for a country
a summary usage rate was calculated using the weighted
average by study population size. The characteristics of
the prenatal medication usage studies are summarized in
Additional file 2.
Because of concerns of changing autism prevalence
rate over time, an a priori decision was made to restrict
the analysis to include autism prevalence studies in
which the range of birth years had at least one year of
overlap with the range of birth years of the prenatal
paracetamol usage studies. If multiple autism prevalence
studies met this criterion for a given country, a weighted
average based on study population size was calculated.
This reduced the number of prenatal exposure studies
used in this analysis to 20. There were inadequate data
available to conduct a U.S. state level analysis.
Data for investigating early life exposure to paracetamol
for circumcision and autism prevalence
To investigate the relationship of early life paracetamol
exposure for male neonates to autism spectrum disorder,
population circumcision rates were compared to male
population autism prevalence rates for two time periods.
Male autism prevalence rates calculated from studies
reported by the Center for Disease Control in the Sum-
mary of Autism/ASD Prevalence Studies (described above)
were compared to male circumcision rates from studies
identified by a systematic search of the peer reviewed
medical literature using the National Library of Medicine’s
Pub Med database. An additional U.S. state level analysis
was done with available data (limited to the more recent
time period) by comparing state and time period stratified
male autism prevalence rates from the U.S. studies from












































Weighted avg. population prenatal Paracetamol Usage Rate 
Country-level Data on Autism/ASD Prevalence and 
Average Prenatal Paracetamol Usage
Countries
r=0.80
Figure 1 Graph of country-level data on Autism/ASD
prevalence and average prenatal paracetamol usage. The
Autism/ASD prevalence and the prenatal paracetamol usage rates
are both population weighted averages of all the respective studies
for a country. (See Additional files 2 and 5).
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Project [46].
Circumcision rates
The circumcision rates were obtained by systematic
search of the peer reviewed medical literature using the
National Library of Medicine’s Pub Med database. A
search of the English language literature on Pub Med
was conducted using the terms circumcision and the dif-
ferent country names. The circumcision rates utilized
the best identified information. If infant circumcision
rates were available, they were utilized over national
rates. If changing rates were presented, the rates for
years closest to the study birth years were utilized. When
a published paper was not available the rate was esti-
mated. The estimation was calculated using the same
methodology as the World Health Organization and the
Circumcision Independent Reference and Commentary
Service, calculated from the sum of the numbers of Jewish
and Muslim males [47,48]. Data for the percentage of Jews
by country were obtained from the Jewish Virtual Library
[49]. Data for the percentage of Muslims by country
were obtained from a Pew Forum report [50]. While
most Jewish and Muslim males are circumcised, true
circumcision rates are unknown and circumcision rates
based upon religion are only an approximation. Both
the World Health Organization and the Circumcision
Independent Reference and Commentary Service indi-
cated that this would likely underestimate the true
prevalence (see Additional file 3). Annual U.S. state
level infant circumcision rates were available for eight
years between 1997 and 2006 from the Health Care
Utilization Project (HCUP) of the Agency for Health
Care Research and Quality (AHRQ) of the United States
Department of Health and Human Services. Thirteen
states had complete data for this eight year period and
an additional seventeen states had partial data [46,51].
For the data analysis, the studies of autism prevalence
were divided into two time periods. The first consisted
of all prevalence studies in which all subjects were born
before 1995 (35 country level studies). The assumption
is that during this time period paracetamol would not
generally have been administered during the circumci-
sion procedure. The second, post-1995 cohort includes
prevalence studies in which some subjects were born
after 1994 (1995+), (20 country level studies) when
circumcision pain was first recognized and treated. The
assumption is that during this time period some portion
of the cohort would have been administered paracetamol
during the circumcision procedure. For countries with
multiple studies in a time period, a summary prevalence
was calculated using a weighted average based on study
population size (Additional file 3). An additional U.S.
state level analysis was conducted for the post-1995cohort. Similarly, for states with multiple studies in a
time period, a summary prevalence was calculated using
a weighted average based on study population size. State
level circumcision data were not available to conduct a
pre-1995 analysis [Additional file 4]. Each of the data
sets was checked for normality using standard graphical
and statistical methods. Within the limits of these small
datasets, the normality assumption was not seriously vio-
lated and so Pearson’s parametric correlation coefficient




For the country-level analyses, synchronous data were
available from 8 countries. A country’s average prenatal
paracetamol consumption was found to be correlated
with its autism/ASD prevalence (r = 0.80, Figure 1 and
Additional file 5). The trend among the 8 countries indi-
cates that a change of 10% in population prenatal para-
cetamol usage was associated with an increased autism
population prevalence of 0.53/1000 persons (95% CI: 0.13
to 0.93) (Figure 1).
Early life exposure
A strong correlation (r = 0.98) was found in the country-
level data between circumcision and autism spectrum
disorder prevalence rates for boys born after 1995 (when
circumcision guidelines began recommending analgesics).
The slope of this trend for the 9 countries with available
data indicates that a change of 10% in the population cir-
cumcision rate was associated with an increase in autism/
ASD prevalence of 2.01/1000 persons (95% CI: 1.68 to
2.34) (Figure 2).
Data were available for 12 countries for boys born before
1995 (Figure 3), and the trend in the data was weaker; the
correlation between circumcision prevalence and autism/
Figure 2 Graph of country and U.S. state- level data on Autism/ASD and circumcision prevalence rates. All studies in which at least some
cohort members were born after 1995. This graph includes country-level studies with the U.S. stratified to state-level studies for the post-1995
cohort (no overall U.S. data point). The assumption is that, due to changes in neonate prescribing practices in the mid-1990s, some cohort
members in each study would likely be exposed to paracetamol at the time of circumcision. Autism rates are population weighted averages of all
studies for a country or U.S. state. (See Additional files 1, 3, 4 and 5).
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the trend was only a sixth of that for the later period for a
10% change in circumcision rate, there was an increase in
autism/ASD prevalence of 0.35/1000 persons (95% CI:
0.22 to 0.47).
Across all country-level studies prior to the widespread
use of paracetamol for circumcision (all born prior to
1995), the weighted average autism/ASD male to female
prevalence ratio was 3.9 to 1. For the post 1995 cohort,
this ratio increased to 5.6 to 1.
Available data allowed a parallel analysis of U.S. states
post-1995, but not for the earlier period. The data for
the 14 U.S. states with available data show a remarkablyFigure 3 Graph of country-level data on Autism/ASD and circumcisio
born before 1995. The assumption is that all of the cohort members in eac
circumcision. U.S. state level data was not available for this pre-1995 cohor
country. (See Additional files 1 and 3).similar pattern to the 8 countries (this set of countries
does not include the U.S. to avoid double counting) for
the same time period (Figure 2, r = 0.95).
Discussion
These ecological analyses identified positive correlations
between autism/ASD prevalence and indicators of both
prenatal and very early life paracetamol exposures. If
these patterns are confirmed in formal epidemiologic
studies, the use of paracetamol during pregnancy and at
the time of circumcision may help to explain autism/
ASD prevalence variations between the sexes, among
countries, and within U.S. states and ethnic groups. Then prevalence rates. All studies in which all cohort members were
h study would not likely be exposed to paracetamol at the time of
t. Autism rates are population weighted averages of all studies for a
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ASD prevalence before and after the recognition of pain
at the time of circumcision is suggestive of a possible
effect caused by the shift to the use of paracetamol. The
change in the overall time period average male to female
autism/ASD prevalence ratio (weighted by study size)
from 3.9 to 1 in the unexposed time period to 5.6 to 1 in
the second time period with a probable paracetamol expos-
ure may also be suggestive an effect from this exposure.
Limitations
It is important to acknowledge that this analysis has
numerous and significant limitations. First and foremost,
correlation is not causation and as such no causal infer-
ence is intended. Homogeneity of exposure and preva-
lence assessment methodologies among the studies has
been assumed, but each may be subject to misclassifica-
tion, confounding and bias. The change in autism/ASD
prevalence, circumcision prevalence and paracetamol
usage rates over time may not have been adequately
addressed. Circumcision rates are presented as a proxy
for an early male neonatal exposure to paracetamol.
However, this assumption is not without significant lim-
itations. The timeline for the actual implementation of
child pain management protocols and the utilization of
paracetamol with circumcision is not known. Addition-
ally, pain management guidelines suggest that paraceta-
mol alone is not sufficient to manage circumcision pain
so a nerve block or local anesthesia may also be admin-
istered, which may be confounding factors. In general,
this type of ecologic study has significant limitations
that severely limit causal inference. Ecologic bias or the
failure of ecological associations to correspond to bio-
logic effects at the individual level is a concern. It has
been shown that the relations seen in country level data
may poorly reflect the relationships that exist on an in-
dividual basis [52]. Despite these limitations, the con-
sistent patterns reported here support the need to
further investigate this potentially important hypothesis.
Prenatal exposure trends
Previous research has identified paracetamol usage
trends that curiously coincide with the rise in prevalence
and population demographics of autism/ASD. In the US
Slone Epidemiology Center Birth Defects study paraceta-
mol was the most commonly used medication amongst
all subjects with usage higher during pregnancy than be-
fore pregnancy. In the early 1980’s about 42% of women
used paracetamol during the first trimester of pregnancy.
The rate climbed to over 65% in the early 1990’s, where
it has essentially remained through 2004 [18]. Maternal
viral infection requiring hospitalization during the first
trimester and maternal bacterial infection in the second
trimester have been associated with diagnosis of ASD inthe offspring (Hazard ratios 2.98 (95% CI: 1.29 to7.15)
and 1.42 (95% CI: 1.08 to1.87), respectively) [53]. In a re-
cent study, maternal self-reported influenza was associ-
ated with a twofold increased risk of infantile autism and
a febrile episode lasting more than seven days was asso-
ciated with a threefold increased risk [54]. Each of these
maternal infections or a prolonged febrile episode would
likely increase the exposure to paracetamol.
In the U.S., usage of paracetamol by pregnant women
mirrors the population demographics of women whose
children develop autism spectrum disorder, by race, age
and education [18,55,56]. The population demographics
for mothers who circumcise their children are also very
similar, with rates increasing with socio-economic status
and insurance coverage rates [57-59]. Studies have
shown that a parent’s own usage rates of paracetamol
and other medications correlate with what they give to
their children, so a similar demographic usage pattern
would be expected for childhood exposure [60,61]. This
synchronous U.S. pattern may be suggestive of an additive
nature of both prenatal and early life exposure to para-
cetamol and a relationship to autism/ASD (Figure 4).
Early life exposure trends
Paracetamol is the most common drug administered to
US children and the predominant analgesic/antipyretic
drug among children up to 24 months of age [62]. Para-
cetamol is suggested for pain management following
vaccinations. In 1983 the average U.S. child received 8
immunizations before age 2. In 2011, the average was
25, a 313% increase [63,64]. From the perspective of the
current hypothesis, these represent increased oppor-
tunities for paracetamol exposure in pain management
(although administering several vaccines at once means
analgesia may not increase proportionally).
A recent study representing one-fifth of all pediatric
hospital admissions in the U.S., identified paracetamol as
the most common drug administered to children over
one year of age and the second most common drug
administered for those under one year; more than 40%
of hospital stays in both groups include paracetamol
[65]. Hospitalization of children and neonates for infection
as well as non-infectious disease have been associated with
increased risk of ASD in a large Danish cohort (hazard
ratios 1.38 (95% CI: 1.31 to 1.43) and 1.76 (95% CI: 1.68 to
1.86), respectively) [66].
Biologic plausibility
Paracetamol has four important metabolic pathways
(Figure 5). The two main pathways are glucuronidation
and sulfation. Paracetamol is mainly metabolized in the
liver via conjugation with glucuronide and sulfate and
then excreted. Both these metabolic routes yield inactive,
non-toxic final products. Glucuronidation is the primary
Figure 4 Comparison of U.S. demographic characteristics. Comparison of U.S. autism prevalence rates, circumcision rate and prenatal
paracetamol usage rates by maternal race, education level and age.
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pathway for paracetamol metabolism until age 10–12 years
[67]. Neonates, in general, have lower capacity to
metabolize drugs due to the underdevelopment of the
glucuronidation pathway and inefficiency and immaturity
in renal function [68]. Three studies of neonates with
postnatal age ranging from 1–3 days obtained a
glucuronidation/sulfation (G/S) ratio between 0.12 and
0.28 [69-71]. This is in contrast to 11 month old childrenFigure 5 Metabolic pathway model for paracetamol.with a significantly higher G/S ratio of about 0.7 and
adults with a G/S ratio approaching 2.0 [71,72]. Low birth
weight and bilirubinemia have also been found to reduce
glucuronidation capacity, both of which have been associ-
ated with autism [73-76]. Autistic children have been
shown to have abnormal sulfate capacity and have been
shown to have a specific inability to sulfate paracetamol
[8,77,78]. Parents of autistic children have also been
shown to have abnormal transsulfuration metabolism
[79]. When the capacity to metabolize through the
primary pathways is depleted or saturated, the fraction of
the dose converted to reactive metabolites increases and
the secondary metabolic pathways become increasingly
involved [80].
One of the two secondary pathways is cytochrome
P-450 (CYP P-450) mediated, forming a highly reactive
metabolite, n-acetyl-p-benzoquinoneimine (NAPQI) which
reacts with cellular glutathione (GSH) to form a non-toxic
conjugate, which is subsequently excreted. Once GSH is
exhausted, NAPQI binds to cellular proteins, including
mitochondrial proteins reducing the ability to detoxify,
which can lead to oxidative stress, immune system acti-
vation, hepatocellular death, nephropathy and asthma
[10,19,81,82]. It has been shown that paracetamol treat-
ment induces greater glutathione depletion in male mice
[11,83]. Alterations in GSH homeostasis have been a
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mothers [84-87]. Also, decreased glutathione levels
have been associated with preeclampsia [88]. In the
Danish Birth Cohort, women who used paracetamol
during the third trimester of pregnancy had increased
risk of preeclampsia RR = 1.40 (95% CI: 1.24 to 1.58)
[89]. In two studies, maternal preeclampsia has been
associated with increased risk of having a child with ASD
(OR = 1.69 (p = .0005) and RR = 1.64 (95% CI: 1.08 to
2.49), respectively) [90,91]. Additionally, during pregnancy
a women’s sulfation capacity is reduced which may pre-
cipitate activation of immune responses, via this P-450
pathway [92,93]. The activation of immune response and
pro- inflammatory cytokine interleukin signaling has re-
cently been detected even at therapeutic doses of paraceta-
mol [10,94]. Converging evidence highlights the important
role of many of the same cytokines in mediating maternal
immune activation effects on the neurodevelopment of
autistic offspring [95-105].
A fourth metabolic pathway, accounting for about 6%
of paracetamol metabolism, has been identified that is
believed to be related to the mechanism of analgesic
action [106]. This pathway involves deacetylation of
paracetamol in the liver producing p-aminophenol that
conjugates with arachidonic acid in the brain and in the
spinal cord [107,108]. P-aminophenol is recognized to
be involved in paracetamol nephrotoxicity [81,109].
More recently, P-aminophenol has been shown to pro-
duce a significant loss in mouse cortical neuron viability
at therapeutic concentrations [12]. This suggests another
possible pathway for a neurotoxic effect of paracetamol
when the principle metabolic routes are exhausted.
In summary, there are several lines of evidence that
suggest that prenatal and or early life paracetamol ex-
posure may adversely affect neurodevelopment. Prenatal
exposure may trigger maternal immune activation with
possible effects on fetal brain development. In early life,
maturational compromises to the glucuronidation path-
way at the time of the circumcision related exposure, in
combination with the compromises to the sulfation path-
way that typify autistic children, may lead to utilization of
the suboptimal secondary metabolic routes with the
potential for adverse neurological effects in susceptible
individuals [110-112].
Conclusions
In this hypothesis generating exploratory analysis, several
lines of evidence support the plausibility of a relationship
between prenatal and early life exposure to paracetamol
and autism spectrum disorder. It is proposed that the use
of paracetamol in pregnancy and/or early childhood may
alter immune processes increasing the risk of autism
spectrum disorder in susceptible individuals. In an eco-
logic analysis, with all the previously discussed limitations,a correlation was found between maternal prenatal use of
paracetamol and autism spectrum disorder. Additionally,
a correlation was identified for the first time between neo-
natal circumcision with a probable paracetamol exposure
and autism spectrum disorder. These relationships along
with the synchronous rise in use of paracetamol and ASD,
the convergence of the potential biologic mechanisms and
the identification of plausible causes of increased male
susceptibility provide consistent evidence of an associ-
ation. Large scale population based epidemiologic studies
are needed to confirm or disprove this association.Additional files
Additional file 1: All Studies Reported in CDC Summary of Autism/
ASD Prevalence Studies. Summary of CDC studies divided into two
groups. The first group has some members born post-1995 (some likely
to be exposed to paracetamol at time of circumcision) and the second
group born pre-1995 (exposure unlikely). The chart displays the study
author, country, year published, range of birth years, ratio of males to
females, study population, and the overall and male ASD prevalence
[113-163].
Additional file 2: Prenatal Paracetamol Exposure Studies Summary.
All prenatal paracetamol studies identified by a systematic search of the
PubMed database. Studies without overlapping birth years with the
autism prevalence studies are denoted with an “*” and were not utilized
in the analysis. The chart displays the study author, country, year
published, range of birth years, the study population, paracetamol usage
rate, and study methodology [164-192].
Additional file 3: Summary of Weighted average Autism studies
and Circumcision Rates by Country. Country weighted averages of
CDC autism studies from Additional file 1. Data is divided into the two
cohorts, pre and post −1995. The chart displays the circumcision rates
and sources for each country and the study weights. The data in this
table is used for the country-level analysis and comparison between the
pre and post −1995 cohorts [193-206].
Additional file 4: U.S. Studies Stratified by State from CDC
Summary of Autism/ASD Prevalence Studies. The six U.S. autism
prevalence studies from Additional file 1 in the post 1995 cohort
stratified by state. Chart displays the study author, country, year
published, range of birth years, ratio of males to females, study
population, the circumcision rates and sources, and the overall and male
ASD prevalence. * Analysis restricted to 2006 data of 8 year olds.
Additional file 5: Summary of Weighted average Autism Prevalence
and Prenatal Exposure to Paracetamol Data. The Autism Prevalence
Studies from Additional file 1 that had overlapping cohort birth years
with the prenatal paracetamol studies in Additional file 2 are
summarized. The study author, country, year published, range of birth
years, population, overall ASD rate, the summary weighted average ASD
rate by country, the weighted average APAP exposure rate,the APAP
study range of birth years and the study weights. This data was used for
Figure 1 and to calculate the prenatal correlation and trend.Abbreviations
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